Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity.

Favresse, Julien; Bayart, Jean-Louis; David, Clara; Dogné, Jean-Michel; Douxfils, Jonathan

Favresse, Julien; Bayart, Jean-Louis; David, Clara; Dogné, Jean-Michel; Douxfils, Jonathan.

Favresse J; Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium; Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium. Electronic address: julien.favresse@slbo.be.
Bayart JL; Department of Laboratory Medicine, Clinique St-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium.
David C; Qualiblood sa, Namur, Belgium.
Dogné JM; Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium.
Douxfils J; Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium; Qualiblood sa, Namur, Belgium.

J Infect ; 84(4): e4-e6, 2022 04.

Article in English | MEDLINE | ID: covidwho-1632194

Subject(s)

COVID-19; SARS-CoV-2; Antibodies, Viral; Humans; Nucleocapsid; Sensitivity and Specificity; Severity of Illness Index; Technology

Keywords

Antigenic assay; COVID-19; RT-PCR; SARS-CoV-2; disease severity

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: J Infect Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google